ANTI CANCER MEDICATION
250 mg Combinib Lapatinib IP Tablets
Price on Request
Combinib 250 mg Lapatinib IP is a targeted anti-cancer medication manufactured by Cipla. Primarily used to treat advanced or metastatic HER2-positive breast cancer, it is a tyrosine kinase inhibitor that blocks abnormal proteins driving cancer cell growth, often prescribed alongside capecitabine, trastuzumab, or hormonal therapies.
liketo.usa,uk,china,southkorea,russia,japan,singapore
liketo.usa,uk,china,southkorea,russia,japan,singapore
Composition
Strength 250 mg
Packaging Size 30 Tablets
Pack Size 30 Tablets
Usage Breast Cancer
Manufactured By Cipla
Prescription/Non Prescription Prescription
Country of Origin Made in India
Composition Lapatinib Tablets IP
Brand Combinib
Form Tablet
Minimum order quantity: 50 Bottle
Enquire About This Product
